It is the researcher's responsibility to provide accurate, complete, and unbiased verbal and written information yet, as this essay discusses, challenges to meaningful research consent abound in the communication between researcher and subject. This discussion of these challenges is far from exhaustive, but it will flag some of the potholes that researchers must anticipate on the sometimes rocky road to eliciting meaningful consent. These include, but are not limited to, inadequate scientific literacy, poorly written consent forms, and even the deployment of scientific terms and seductive acronyms like CURE and MIRACL. Studies with acronyms, for example, enroll five times as many patients as those without, are more likely to be published by prestigious journals, and have higher Jadad methodologic quality scores although they are no more likely to conclude with positive findings. Other barriers to researcher-subject communication include: widely differing beliefs and customs, semiotics, socioeconomic status, iatrophobia, and dramatically different histories of treatment in the medical-research arena.
J. W.Jones, L. B.McCullough, and B. W.Richman, “Informed Consent: It's Not Just Signing a Form,”Thoracic Surg Clinics15, no. 4 (2005): 451–460.
3.
D.Brennan, “Informed Consent Forms: Are They Readable?” Southern University Illinois at Carbondale, Open SIUC Honors Theses, Paper 211 (1996).
4.
J. B.Schorling and J.Terry Saunders, “Is ‘Sugar’ the Same as Diabetes? A Community-Based Study Among Rural African-Americans,”Diabetes Care23, no. 3 (March2000): 330–334.
5.
D. L.Roter, R. ERude, and J. Comings, “Patient Literacy: A Barrier to Quality of Care,”Journal of General Internal Medicine13, no. 12 (1998): 850–851.
J. R.Ogloff and R. K. Otto, “Are Research Participants Truly Informed? Readability of Informed Consent Forms Used in Research,”Ethics and Behavior1, no. 4 (1991): 239-252. This essay seeks to show that words are powerful and that word choices can limit our ability to carry out the communication mandates upon which consent rests.
8.
T.Mann, “Informed Consent for Psychological Research: Do Subjects Comprehend Consent Forms and Understand Their Legal Rights?”Psychological Science5, no. 3 (1994): 140–143.
9.
See Brennan, supra note 4.
10.
J. A.Longo, The Fry Graph: Validation of the College Levels,”Journal of Reading26, no. 3 (1982): 229-234; T. M. Grunder, “Two Formulas for Determining the Readability of Subject Consent Forms,” American Psychologist 33, no. 8 (1978): 773-775 K. M. Cordasco, “Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices,” in Obtaining Informed Consent From Patients: Brief Update Review, Evidence Reports/Technology Assessments, No. 211, Agency for Healthcare Research and Quality (US), March 2013.
11.
W. C.Waggoner and D. M.Mayo, “Who Understands? A Survey of 25 Words or Phrases Commonly Used in Proposed Clinical Research Consent Forms,”IRB: Ethics & Human Research17, no. 1 (1995): 6–9.
12.
H. A.Washington, “Prudence and the Pill: Testing Thalidomide in the Global South, Biopolitical Times, December13, 2010, available at < http://www.biopoliticaltimes.org/article.php?id=5504> (last visited July 20, 2016).
13.
T.Mann, “Informed Consent for Psychological Research: Do Subjects Comprehend Consent Forms and Understand Their Legal Rights?”Psychological Science5, no. 3 (1994): 140–143.
14.
A. M.Hornblum, Acres of Skin: Human Experiments at Holmesburg Prison (New York: Routledge, 1999).
15.
See Mann, supra note 13.
16.
E.Rothwellet al., “A Randomized Controlled Trial of an Electronic Informed Consent Process,”Journal of Empirical Research on Human Research Ethics9, no. 5 (2014): 1–7.
17.
Id.
18.
K.Cordasco, “Making Health Care Safer II: An Updated Critical Analysis of the Evidence for Patient Safety Practices,” in Obtaining Informed Consent From Patients: Brief Update Review, Evidence Reports/Technology Assessments, No. 211, Agency for Healthcare Research and Quality (US), March 2013.
19.
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators, “Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without St-Segment Elevation,”New England Journal of Medicine345, no. 7 (2001): 494–502
20.
Id.
21.
P.Sleight, The HOPE (Heart Outcomes Prevention Evaluation) Study,”Journal of the Renin Angiotensin Aldosterone System1, no. 1 (2000): 18–20.
J. A.Bargh, S.Chaiken, and R.Governderet al., “The Generality of the Automatic Attitude Activation Effect,”Journal of Personality and Social Psychology62, no. 6 (1992): 893–912.
24.
Id.
25.
I'm indebted to James P.Orlowski and James A.Christensen's paper, “The Potentially Coercive Nature of Some Clinical Research Trial Acronyms,” for some of these examples.
26.
J.Hausleiteret al., “Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients with In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS)Study,”Circulation110, no. 7 (2004): 790–795.
27.
R.Bauersachs and S. D.Berkowitzet al., “Oral Rivaroxaban for Symptomatic Venous Thromboembolism,”New England Journal of Medicine 363 (2010): 2499–2510.
28.
M.B.Stanbrook, P. C.Austin, and D. A.Redelmeier, “Acronym-Named Randomized Trials in Medicine — The ART in Medicine Study,”New England Journal of Medicine355, no. 1 (2006): 101–102.
29.
T. O.Cheng, “Acronyms of Clinical Trials in Cardiology—1998,”American Heart Journal137, no. 4 (1998) 726–765.
30.
J. P.Orlowski and J. A.Christensen, “The Potentially Coercive Nature of Some Clinical Research Trial Acronyms,”Chest121, no. 6 (2002): 2023–2028.
31.
Id.
32.
The Office of Medical Products and Tobaccoet al., “Informed Consent Information Sheet: Guidance for IRBs, Clinical Investigators, and Sponsors: Draft Guidance,”available at <http://www.fda.gov/RegulatoryInformation/Guidances/ucm404975.htm> (last visited July 15, 2016).
33.
C.Labos, “The Alphabet Soup of Clinical Trial Acronyms ACRONYM: An Albeit Cool but Really Obtuse Naming Strategy for Medical Studies,”Medscape <http://www.medscape.com/viewarticle/857543> (last visited May 2016).
WilliamStrunk, Jr., The Elements of Style(Project Gutenberg EBook of 1920 edition; Harcourt, Brace and Company New York): at Chapter V, available at <http://www.gutenberg.org/files/37134/37134-h/37134-h.htm> (last visited July 22, 2016).
41.
B. T.Peterson, S. J.Clancy, K.Champion, and J. W.McLarty, “Improving Readability of Consent Forms: What the Computers May Not Tell You,”IRB: A Review of Human Subjects Research14, no. 6 (1992): 6–8.
42.
“Burking in Baltimore,”Baltimore Sun, December13, 1886;B. Jensen, “Blood Money,” Baltimore City Paper, 1998; J. Jasper, “Body Snatching” Baltimore Afro-American, September 4, 1954,available at <https://news.google.com/newspapers?nid=2211&dat=19540904&id=kZwlAAAAIBAJ&sjid=pfUFAAAAIBAJ&pg=2262,815382&hl=en> (last visied July 20, 2016); L. Rosner, The Anatomy Murders: Being the True and Spectacular History of Edinburgh's Notorious Burke and Hare and of the Man of Science Who Abetted Them in the Commission of Their Most Heinous Crimes (Philidelphia:University of Pennsylvania Press, 2009).
43.
H. A.Washington, Medical Apartheid: The Dark History of Experimentation from Colonial Times to the Present, (New York: Doubleday, 2007)
44.
H. A.Washington, “Henrietta Lacks, Unsung Hero,”Emerge Magazine, October1995; H. A. Washington, Deadly Monopolies: The Shocking Corporate Takeover of Life Itself—and the Consequences for Your Health and Our Medical Future (New York: Doubleday, 2011): 46–56.
45.
G.Kolata, “Johns Hopkins Admits Fault in Fatal Experiment,”New York Times, July17, 2001.
46.
Ericka Grimes V. Kennedy Krieger Institute, Inc., Myron Higgins, a minor, etc., et al., v. Kennedy Krieger Institute, Inc., Court of Appeals of Maryland, Nos. 128, 129, Sept. Term, 2000, Decided: August 16, 2001, available at <http://case-law.findlaw.com/md-court-of-appeals/1236870.html#sthash.M0Rdr5BO.dpuf> (last visited July 15, 2016).
47.
CBS, “Baltimore Ranked One of the Poorest Cities in America,”February18, 2015.
48.
M. S.Rosenwald and M. A.Fletcher, “Why Couldn't 130 Million Transform One of Baltimore's Poorest Places?”Baltimore Sun, May2, 2016.
49.
D.Haraway, “Situated Knowledges: The Science Question in Feminism and the Privilege of Partial Perspective,”Feminist Studies14, no. 3 (1988): 575–599.
50.
H. A.Washington, Medical Apartheid: The Dark History of Experimentation from Colonial Times to the Present(New York: Doubleday, 2007); J. Walter Fisher, “Physicians and Slavery in the Antebellum Southern Medical Journal,” Journal of the History of Medicine and Allied Sciences XXIII (January 1968): 45; “Surgery and the Negro Physician: Some Parallels in Background,” National Medical Association Journal XLIII (May 1951): 145-52; T. L. Savitt, Medicine and Slavery: The Diseases and Health Care of Blacks in Antebellum Virginia, (Champaign University of Illinois Press, 1981); also, W. Fisher, “The Use of Blacks for Medical Experimentation and Demonstration in the Old South,” Journal of Southern History 48, no. 3 (1982): 331-348; W. Weyers, The Abuse of Man: An Illustrated History of Dubious Medical Experimentation (New York: Ardor Scribendi, 2007); W. U. Eckart, Medizin und Kolonialimperialismus: Deutschland 1884–1945 (Paderborn: Schöningh, 1997); W. M. Byrd and L. A. Clayton, An American Health Dilemma: Race, Medicine, and Health Care in the United States, 1900-2000 (Boston: Routledge, 2000).
51.
See Washington, supra note 43, at 263–299.
52.
F.Enquselassie, J.Nokes, and F.Cutts, “Communities’ Confidentiality Should Be Maintained and Community Consent Sought,”BMJ312, no. 7022 (1996): 54-55; R. Crawshaw, M. J. Garland, B. Hines, and C. Lobitz, “Oregon Health Decisions: An Experiment with Informed Community Consent,” JAMA 254, no. 22 (1985): 3213-3216; J. Cassell and A. Young, “Why We Should Not Seek Individual Informed Consent for Participation in Health Services Research,” Journal of Medical Ethics 28, no. 5 (2002): 313-317; C. Blohm, J. Simon, “Group Consent in Population Based Research,” Journal de International Bioethique 19, no. 3 (2008): 49-67, 123.
53.
J.Katz, “Blurring the Lines: Research, Therapy, and IRBs,”The Hastings Center Report27, no. 1 (1997): 9-11, available at <http://www.jstor.org/stable/3528019> (last visited July 15, 2016).
54.
C.Natanson, S. J.Kern, and P.Lurieet al., “Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Risk of Myocardial Infarction and Death: A Meta-Analysis,”JAMA299, no. 19 (2008): 2304–2312.
55.
See Katz, supra note 53.
56.
W. C.Waggoner and D. M.Mayo, “Who Understands? A Survey of 25 Words or Phrases Commonly Used in Proposed Clinical Research Consent Forms,”IRB: A Review of Human Subjects Research17, no. 1 (1995): 6–9.
57.
Kunen mused that “[t]here is no greater example of the power of an adjective to modify a noun than the use of the word ‘legal’ before the word ‘ethics’.”
58.
Nuremberg Military Tribunal s, 1949-1953, Vol. 2 of Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law, No. 10.,Nuremberg, October 1946-April1949, Washington, D.C.: GPO, available at <https://www.loc.gov/rr/frd/Military_Law/pdf/NT_war-criminals_Vol-II.pdf> (last accessed July 20, 2016.)
59.
H. A.Washington, Medical Apartheid: The Dark History of Experimentation from Colonial Times to the Present (New York: Doubleday, 2007).
60.
Advisory Committee on Human Radiation Experiments, Final Report of the Advisory Committee on Human Radiation Experiments(Washington, D.C.: U.S. Government Printing Office, 1995): 734.
61.
C.Elliott, “Whatever Happened to Human Experimentation?”Hastings Center Report46 (2016): 1–4.
62.
G.Orwell, “Appendix: The Principles of Newspeak,” in Nineteen Eighty-Four, Project Gutenberg of Australia eBook No. 0100021.txt, 2001, available at <http://gutenberg.net.au/ebooks01/0100021.txt> (last visited July 15, 2016).
